Good find Ron. But wait a minute I thought Entest was sold to Peiwen YU, so why does this say below that IP was assigned by Entest and is controlled by Koos to start this new company?
As of July 21, 2020 we have not licensed, developed or commercialized any existing therapies. On July 14,2020 we were assigned all right, title, and interest to intellectual property related to methods, devices, and techniques useful for enhancing function of a cellular graft through photoceutical manipulation. These rights were assigned to us by the Company’s Chief Executive Officer and Entest BioMedical, Inc., a California corporation controlled by the Company’s Chief Executive Officer. This intellectual property forms the basis of the Company’s first medical applications under development (“Cell Transplant IP”).
News 
Market Data 
Discover 
